Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 21 studies | 52% ± 15% | |
brain | 20 studies | 49% ± 19% | |
lung | 19 studies | 53% ± 15% | |
intestine | 12 studies | 37% ± 18% | |
eye | 10 studies | 45% ± 18% | |
kidney | 9 studies | 51% ± 13% | |
liver | 8 studies | 36% ± 14% | |
bone marrow | 6 studies | 45% ± 21% | |
pancreas | 5 studies | 64% ± 29% | |
heart | 5 studies | 27% ± 6% | |
uterus | 5 studies | 58% ± 17% | |
prostate | 5 studies | 37% ± 6% | |
lymph node | 5 studies | 41% ± 27% | |
placenta | 4 studies | 78% ± 22% | |
adipose | 4 studies | 50% ± 11% | |
breast | 4 studies | 50% ± 7% | |
adrenal gland | 3 studies | 36% ± 4% | |
esophagus | 3 studies | 53% ± 23% | |
skin | 3 studies | 44% ± 9% | |
thymus | 3 studies | 55% ± 20% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 60737.72 | 653 / 653 | 100% | 2212.03 | 604 / 605 |
ovary | 100% | 72638.92 | 180 / 180 | 100% | 1192.79 | 429 / 430 |
breast | 100% | 66864.60 | 459 / 459 | 100% | 1983.81 | 1114 / 1118 |
skin | 100% | 54701.61 | 1808 / 1809 | 100% | 3002.92 | 470 / 472 |
lung | 100% | 87623.93 | 578 / 578 | 99% | 1877.20 | 1149 / 1155 |
prostate | 100% | 50667.38 | 245 / 245 | 99% | 1634.89 | 499 / 502 |
brain | 99% | 58662.42 | 2624 / 2642 | 100% | 2417.10 | 705 / 705 |
stomach | 100% | 52359.87 | 359 / 359 | 99% | 1185.76 | 284 / 286 |
liver | 100% | 36488.51 | 226 / 226 | 99% | 1189.06 | 403 / 406 |
uterus | 100% | 73031.72 | 170 / 170 | 99% | 1306.43 | 455 / 459 |
kidney | 100% | 66082.24 | 89 / 89 | 99% | 2277.30 | 893 / 901 |
esophagus | 100% | 41907.52 | 1444 / 1445 | 99% | 1034.61 | 181 / 183 |
intestine | 100% | 50973.61 | 966 / 966 | 99% | 1163.15 | 520 / 527 |
adrenal gland | 100% | 116721.43 | 258 / 258 | 98% | 2397.82 | 226 / 230 |
pancreas | 99% | 29466.07 | 325 / 328 | 99% | 1681.19 | 176 / 178 |
bladder | 100% | 57387.05 | 21 / 21 | 97% | 1415.08 | 491 / 504 |
adipose | 100% | 81445.41 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 83183.79 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 2829.76 | 29 / 29 |
muscle | 100% | 70714.54 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 104569.42 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 1396.04 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 662.55 | 1 / 1 |
peripheral blood | 100% | 97898.69 | 927 / 929 | 0% | 0 | 0 / 0 |
heart | 99% | 73332.77 | 851 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 1381.13 | 79 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0060742 | Biological process | epithelial cell differentiation involved in prostate gland development |
GO_1903771 | Biological process | positive regulation of beta-galactosidase activity |
GO_0007041 | Biological process | lysosomal transport |
GO_0019216 | Biological process | regulation of lipid metabolic process |
GO_0060736 | Biological process | prostate gland growth |
GO_0006665 | Biological process | sphingolipid metabolic process |
GO_1905572 | Biological process | ganglioside GM1 transport to membrane |
GO_0010506 | Biological process | regulation of autophagy |
GO_0007193 | Biological process | adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0005764 | Cellular component | lysosome |
GO_0035577 | Cellular component | azurophil granule membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0005770 | Cellular component | late endosome |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0043202 | Cellular component | lysosomal lumen |
GO_0005765 | Cellular component | lysosomal membrane |
GO_0008047 | Molecular function | enzyme activator activity |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0005543 | Molecular function | phospholipid binding |
GO_1905576 | Molecular function | ganglioside GT1b binding |
GO_1905577 | Molecular function | ganglioside GP1c binding |
GO_1905575 | Molecular function | ganglioside GM3 binding |
GO_0002020 | Molecular function | protease binding |
GO_0097110 | Molecular function | scaffold protein binding |
GO_1905573 | Molecular function | ganglioside GM1 binding |
GO_1905574 | Molecular function | ganglioside GM2 binding |
GO_0005515 | Molecular function | protein binding |
Gene name | PSAP |
Protein name | Prosaposin (Proactivator polypeptide) [Cleaved into: Saposin-A (Protein A); Saposin-B-Val; Saposin-B (Cerebroside sulfate activator) (CSAct) (Dispersin) (Sphingolipid activator protein 1) (SAP-1) (Sulfatide/GM1 activator); Saposin-C (A1 activator) (Co-beta-glucosidase) (Glucosylceramidase activator) (Sphingolipid activator protein 2) (SAP-2); Saposin-D (Component C) (Protein C)] Prosaposin Alternative protein PSAP |
Synonyms | SAP1 GLBA |
Description | FUNCTION: Saposin-A and saposin-C stimulate the hydrolysis of glucosylceramide by beta-glucosylceramidase (EC 3.2.1.45) and galactosylceramide by beta-galactosylceramidase (EC 3.2.1.46). Saposin-C apparently acts by combining with the enzyme and acidic lipid to form an activated complex, rather than by solubilizing the substrate.; FUNCTION: Saposin-B stimulates the hydrolysis of galacto-cerebroside sulfate by arylsulfatase A (EC 3.1.6.8), GM1 gangliosides by beta-galactosidase (EC 3.2.1.23) and globotriaosylceramide by alpha-galactosidase A (EC 3.2.1.22). Saposin-B forms a solubilizing complex with the substrates of the sphingolipid hydrolases.; FUNCTION: Saposin-D is a specific sphingomyelin phosphodiesterase activator (EC 3.1.4.12).; FUNCTION: [Prosaposin]: Behaves as a myelinotrophic and neurotrophic factor, these effects are mediated by its G-protein-coupled receptors, GPR37 and GPR37L1, undergoing ligand-mediated internalization followed by ERK phosphorylation signaling. .; FUNCTION: Saposins are specific low-molecular mass non-enzymic proteins, they participate in the lysosomal degradation of sphingolipids, which takes place by the sequential action of specific hydrolases. FUNCTION: Saposin-A and saposin-C stimulate the hydrolysis of glucosylceramide by beta-glucosylceramidase (EC 3.2.1.45) and galactosylceramide by beta-galactosylceramidase (EC 3.2.1.46). Saposin-C apparently acts by combining with the enzyme and acidic lipid to form an activated complex, rather than by solubilizing the substrate. .; FUNCTION: Saposin-B stimulates the hydrolysis of galacto-cerebroside sulfate by arylsulfatase A (EC 3.1.6.8), GM1 gangliosides by beta-galactosidase (EC 3.2.1.23) and globotriaosylceramide by alpha-galactosidase A (EC 3.2.1.22). Saposin-B forms a solubilizing complex with the substrates of the sphingolipid hydrolases. .; FUNCTION: Saposin-D is a specific sphingomyelin phosphodiesterase activator (EC 3.1.4.12). . FUNCTION: Saposin-A and saposin-C stimulate the hydrolysis of glucosylceramide by beta-glucosylceramidase (EC 3.2.1.45) and galactosylceramide by beta-galactosylceramidase (EC 3.2.1.46). Saposin-C apparently acts by combining with the enzyme and acidic lipid to form an activated complex, rather than by solubilizing the substrate. . |
Accessions | L8EA14 P07602 A0A0J9YXB8 ENST00000633965.1 Q5BJH1 ENST00000394936.8 [P07602-1] |